MedPath

Calf Muscle Perfusion in Patients With Intermittent Claudication by 3D-reconstruction of MSOT (MSOT_IC_3D)

Recruiting
Conditions
Peripheral Arterial Disease
Intermittent Claudication
Diagnostic Imaging
Interventions
Diagnostic Test: MSOT
Registration Number
NCT05773534
Lead Sponsor
Ulrich Rother
Brief Summary

The aim of the proposed study is to define independent parameters for the diagnostic assessment of the perfusion situation of the calf muscle based on 3D-reconstruction of multispectral optoacoustic tomography (MSOT) in a cross-sectional collective of patients with PAD in Fontaine stage II and a healthy control group.

Detailed Description

This is a monocentric, prospective cross-sectional study which aims to compare the 3D-reconstructed optoacoustic signals in calf muscle after a exercise in patients with PAD in Fontaine stage II and a healthy control group in order to define MSOT thresholds. MSOT data will be correlated with CCDS, ABI, maximum walking distance in 6MWT, subjectively perceived absolute walking distance in everyday life, PAD-related life quality (VASCUQOL-6) and TASC II classification in angiographic imaging (only in case angiographic imaging is available and independent from this study).

Patients with intermittent claudication will be recruited during the consulting hours of the Department of Vascular Surgery, University Hospital Erlangen. Healthy volunteers will be acquired via posters in the clinic. Following detailed information about the study and after providing written consent, relevant clinical data will be collected from the electronical patient file, if available. In addition, a thorough anamnesis interview for relevant data and CCDS would be performed. Afterwards, the 3D-reconstructed parameters will be recorded by means of longitudinal MSOT scans before and after a heel raise exercise until the occurrence of claudication pain in the calf muscle. For patients with PAD, the more affected leg is examined. In healthy volunteers, either leg is examined. ABI would be measured before and after 6MWT. All data will be adequately pseudonymized in compliance with data protection regulations before they are used for statistical analysis. The duration of the study for participants will be max. 90 minutes. The angiographic imaging will be reviewed and analyzed (if available, independently from this study and the interval between MSOT measurement being lesser than 12 months). The complete study including the validation of the data by an independent study group is expected to be finished within one year.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients with PAD in Fontaine stage II or Rutherford category 1-3 or healthy volunteers
  • Adults (>18 years) who are able to give their consent
Exclusion Criteria
  • Patients with PAD in Fontaine stage I, III and IV or Rutherford category 0, 4, 5 and 6 or healthy volunteers with diabetes mellitus, chronic renal failure, claudication symptoms, abnormal ABI or non-palpable foot pulses
  • People with age under 18
  • Absence of written consent
  • Safety concerns of the study physician (person with physical, mental or psychiatric conditions which, by the judgement of the study physician, would compromise the person's safety or the quality of the data, thereby rendering the person an ineligible candidate for the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
healthy groupMSOTMultispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of one leg in healthy volunteers Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s
Patients with PAD in Fontaine stage IIMSOTMultispectral Optoacoustic Tomography (MSOT) of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s
Primary Outcome Measures
NameTimeMethod
Optimal diagnostic MSOT thresholdssingle time point (1 day)

Quantitative oxygenated hemoglobin signal in 3D-reconstruction (in arbitrary units).

\[This target variable is collected non-invasively using MSOT\].

Secondary Outcome Measures
NameTimeMethod
Correlation of acquired 3D-reconstructed MSOT parameters with the subjectively perceived maximum walking distance in everyday lifesingle time point (1 day)

hemoglobin-associated, 3D-reconstructed MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with the subjectively perceived maximum walking distance in everyday life

Confounder analysissingle time point (1 day)

• Correlation of all collected parameters (anamnestic, demographic, physiological) with regard to their characteristics as basic confounders for the MSOT technique

Reperfusion profiles of hemoglobin-associated 3D-reconstructed MSOT parameterssingle time point (1 day)

i.e. the curves of hemoglobin-associated MSOT parameters in the first ten minutes after exercise

Correlation of acquired 3D-reconstructed MSOT parameters with the CCDS flow profiles and PSVssingle time point (1 day)

hemoglobin-associated MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT in patients with PAD in Fontaine stage II correlated with the flow profiles and PSVs of A. femoralis communis and A. poplitea determined by CCDS

Correlation of acquired 3D-reconstructed MSOT parameters with the ABIsingle time point (1 day)

hemoglobin-associated MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with the ABI measurements

Correlation of acquired 3D-reconstructed MSOT parameters with relative (until the first occurrence of pain) and absolute walking distance (until the first stopping due to pain) determined during the 6MWTsingle time point (1 day)

hemoglobin-associated MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with relative (until the first occurrence of pain) and absolute walking distance (until the first stopping due to pain)

Correlation of acquired 3D-reconstructed MSOT parameters with the perceived PAD-specific quality of life (VASCUQOL-6 questionnaire)single time point (1 day)

hemoglobin-associated, 3D-reconstructed MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with the perceived PAD-specific quality of life (VASCUQOL-6 questionnaire)

Difference between the corresponding 3D-reconstructed MSOT values before and after exercisesingle time point (1 day)

Difference of the values before and after exercise for hemoglobin-associated parameters derived by transcutaneous MSOT inpatients in intermittent claudication stage

Correlation of the acquired 3D-reconstructed MSOT parameters with the TASC-classification (angiography)single time point (1 day)

hemoglobin-associated, 3D-reconstructed MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT in patients with PAD in Fontaine stage II correlated with the TASC-classification (angiography)

Correlation of acquired 3D-reconstructed MSOT parameters with maximum walking distance in the 6MWTsingle time point (1 day)

hemoglobin-associated, 3D-reconstructed MSOT parameters (units: arbitrary units (a.u.)) derived by transcutaneous MSOT correlated with the maximum walking distance in the 6MWT

Trial Locations

Locations (1)

University of Erlangen-Nuremberg (FAU), Department of Vascular Surgery

🇩🇪

Erlangen, Bavaria, Germany

© Copyright 2025. All Rights Reserved by MedPath